Your browser doesn't support javascript.
loading
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.
Greenberg, Lauren; Ryom, Lene; Neesgaard, Bastian; Wandeler, Gilles; Staub, Therese; Gisinger, Martin; Skoll, Michael; Günthard, Huldrych F; Scherrer, Alexandra; Mussini, Cristina; Smith, Colette; Johnson, Margaret; De Wit, Stéphane; Necsoi, Coca; Pradier, Christian; Wit, Ferdinand; Lehmann, Clara; d'Arminio Monforte, Antonella; Miró, Jose M; Castagna, Antonella; Spagnuolo, Vincenzo; Sönnerborg, Anders; Law, Matthew; Hutchinson, Jolie; Chkhartishvili, Nikoloz; Bolokadze, Natalia; Wasmuth, Jan-Christian; Stephan, Christoph; Vannappagari, Vani; Rogatto, Felipe; Llibre, Josep M; Duvivier, Claudine; Hoy, Jennifer; Bloch, Mark; Bucher, Heiner C; Calmy, Alexandra; Volny Anne, Alain; Pelchen-Matthews, Annegret; Lundgren, Jens D; Peters, Lars; Bansi-Matharu, Loveleen; Mocroft, Amanda.
Afiliação
  • Greenberg L; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom.
  • Ryom L; Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Neesgaard B; Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Wandeler G; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Staub T; Infectious Diseases, Centre Hospitalier Luxembourg (CHL), Luxembourg City, Luxembourg.
  • Gisinger M; Medizinische Universität Innsbruck , Innsbruck, Austria.
  • Skoll M; Wiener Medizinische Universität, Vienna, Austria.
  • Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Scherrer A; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Mussini C; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Smith C; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Johnson M; Modena HIV Cohort, Università degli Studi di Modena , Modena, Italy.
  • De Wit S; Royal Free HIV Cohort Study, Royal Free Hospital, University College London, London, United Kingdom.
  • Necsoi C; Royal Free HIV Cohort Study, Royal Free Hospital, University College London, London, United Kingdom.
  • Pradier C; Saint Pierre University Hospital, Université Libre de Bruxelles , Brussels, Belgium.
  • Wit F; Saint Pierre University Hospital, Université Libre de Bruxelles , Brussels, Belgium.
  • Lehmann C; Nice HIV Cohort, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France.
  • d'Arminio Monforte A; AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA), Stichting HIV Monitoring (SHM), Amsterdam, The Netherlands.
  • Miró JM; University Hospital Cologne, Cologne, Germany.
  • Castagna A; Italian Cohort Naive Antiretrovirals, (ICONA) L'Azienda Socio Sanitaria Territoriale (ASST) Santi Paolo e Carlo , Milano, Italy.
  • Spagnuolo V; Hospital Clinic-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Sönnerborg A; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
  • Law M; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
  • Hutchinson J; Division of Infectious Diseases, Karolinska Institutet and Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Chkhartishvili N; Australian HIV Observational Database (AHOD), University of New South Wales (UNSW) , Sydney Australia.
  • Bolokadze N; Australian HIV Observational Database (AHOD), University of New South Wales (UNSW) , Sydney Australia.
  • Wasmuth JC; Georgian National AIDS Health Information System (AIDS HIS), Infectious Diseases, AIDS and Clinical Immunology Research Center , Tbilisi, Georgia.
  • Stephan C; Georgian National AIDS Health Information System (AIDS HIS), Infectious Diseases, AIDS and Clinical Immunology Research Center , Tbilisi, Georgia.
  • Vannappagari V; University Hospital Bonn, Bonn, Germany.
  • Rogatto F; Medical Department No. 2, Infectious Diseases Unit, Goethe-University Hospital Frankfurt, Frankfurt, Germany.
  • Llibre JM; ViiV Healthcare, RTP, Research Triangle Park, North Carolina, USA.
  • Duvivier C; Gilead science, Foster City, California, USA.
  • Hoy J; Hospital Universitari Germans Trias i Pujol Department of Internal Medicine, HIV Unit, Barcelona, Spain.
  • Bloch M; Assistance Publique - Hôpitaux de Paris (APHP)-Hôpital Necker-Enfants Malades, Service de Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Institut hospitalo-universitaire (IHU) Imagine , Paris, France.
  • Bucher HC; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
  • Calmy A; Australian HIV Observational Database (AHOD), University of New South Wales (UNSW) , Sydney Australia.
  • Volny Anne A; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Pelchen-Matthews A; HIV/AIDS Unit in Geneva University Hospital, Geneva, Switzerland.
  • Lundgren JD; European AIDS Treatment Group, Brussels, Belgium.
  • Peters L; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom.
  • Bansi-Matharu L; Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Mocroft A; Centre of Excellence for Health, Immunity and Infections (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Clin Infect Dis ; 73(7): e2323-e2333, 2021 10 05.
Article em En | MEDLINE | ID: mdl-33354721
ABSTRACT

BACKGROUND:

Limited data exist that compare clinical outcomes of 2-drug regimens (2DRs) and 3-drug regimens (3DRs) in people living with human immunodeficiency virus.

METHODS:

Antiretroviral treatment-experienced individuals in the International Cohort Consortium of Infectious Diseases (RESPOND) who switched to a new 2DR or 3DR from 1 January 2012-1 October 2018 were included. The incidence of clinical events (AIDS, non-AIDS cancer, cardiovascular disease, end-stage liver and renal disease, death) was compared between regimens using Poisson regression.

RESULTS:

Of 9791 individuals included, 1088 (11.1%) started 2DRs and 8703 (88.9%) started 3DRs. The most common 2DRs were dolutegravir plus lamivudine (22.8%) and raltegravir plus boosted darunavir (19.8%); the most common 3DR was dolutegravir plus 2 nucleoside reverse transcriptase inhibitors (46.9%). Individuals on 2DRs were older (median, 52.6 years [interquartile range, 46.7-59.0] vs 47.7 [39.7-54.3]), and a higher proportion had ≥1 comorbidity (81.6% vs 73.9%). There were 619 events during 27 159 person-years of follow-up (PYFU) 540 (incidence rate [IR] 22.5/1000 PYFU; 95% confidence interval [CI] 20.7-24.5) on 3DRs and 79 (30.9/1000 PYFU; 95% CI 24.8-38.5) on 2DRs. The most common events were death (7.5/1000 PYFU; 95% CI 6.5-8.6) and non-AIDS cancer (5.8/1000 PYFU; 95% CI 4.9-6.8). After adjustment for baseline demographic and clinical characteristics, there was a similar incidence of events on both regimen types (2DRs vs 3DRs IR ratio, 0.92; 95% CI .72-1.19; P = .53).

CONCLUSIONS:

This is the first large, international cohort to assess clinical outcomes on 2DRs. After accounting for baseline characteristics, there was a similar incidence of events on 2DRs and 3DRs. 2DRs appear to be a viable treatment option with regard to clinical outcomes. Further research on resistance barriers and long-term durability of 2DRs is needed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Infecções por HIV / Fármacos Anti-HIV Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Infecções por HIV / Fármacos Anti-HIV Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article